 | |
 | |
| Clinical data | |
|---|---|
| Other names | Dimeditiapramine; Ro 11-1781 |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.054.992 |
| Chemical and physical data | |
| Formula | C26H37NO8S2 |
| Molar mass | 555.70 g·mol−1 |
| 3D model (JSmol) | |
| |
Tiapamil (INN; also known asdimeditiapramine) is a calcium antagonist orcalcium channel blocker.[1][2] It is an experimental drug that has never been marketed.[3]
Tiapamil has been described as anantianginal agent. It exhibits properties of anti-arrhythmic medications. These are medications that are used to treat unusually fast or irregular heartbeats. Examples of arrhytmthic conditions includeatrial fibrillation,atrial flutter, andsuper-ventricular tachycardia.[4] Upon research, the drug shows promising effects on treatment of these condition. Research seeks to create a treatment with tiapamil in order to mitigate the side effects of the more commonly prescribed calcium antagonist and anti-hypertensiveverapamil. The two drugs have similar properties; however, tiapamil appears to treat arrhythmic conditions without many of the hypotensive, negative inotropic, and negative chronotropic side effects. Tiapamil is a calcium channel blocker that acts on the slow calcium channels. It can treat ventricular arrhythmias to a higher degree than traditional calcium antagonists.[medical citation needed]
